NewAmsterdam Pharma Company N.V. is a biopharmaceutical company that aims to improve patient care. It focuses on populations with metabolic diseases and has a lead investigational candidate called obicetrapib, which targets CETP to reduce LDL-C and increase HDL-C. The company was founded in 2019 and is based in Naarden, the Netherlands.